One approach that has attracted much interest is activation of nuclear hormone receptors, which has shown therapeutic potential in several major human diseases [5, 6]; agonists for estrogen receptor-β, retinoic acid receptor-α, and retinoid X receptor have demonstrated prodifferentiation, antiproliferative, and/or proapoptotic effects in a variety of cancers and cancer-related systems [7]. This evidence concerns the gene NR0B1 and cancer.